Table 1. Baseline characteristics.
| Characteristics | Patients | P-value | ||
|---|---|---|---|---|
| All | VTE-positive | VTE-negative | ||
| (n = 103) | (n = 17) | (n = 86) | ||
| Age (years), median (range) | 65 (36–81) | 67 (36–79) | 64 (42–81) | 0.53 |
| Sex, n (%) | 0.23 | |||
| Male | 56 (54.4) | 7 (41.2) | 49 (57.0) | |
| Female | 47 (45.6) | 10 (58.8) | 37 (43.0) | |
| BMI, mean (range) | 20.3 | 20.0 | 20.4 | 0.34 |
| (14.9–28.7) | (16.3–24.6) | (14.9–28.7) | ||
| ECOG PS, n (%) | 0.65 | |||
| 0 | 45 (43.7) | 6 (35.3) | 38 (44.2) | |
| 1 | 57 (55.3) | 11 (64.7) | 47 (54.7) | |
| 2 | 1 (1.0) | 0 (0.0) | 1 (1.1) | |
| Stage, n (%) | 0.10 | |||
| Locally advanced | 37 (35.9) | 3 (17.6) | 34 (39.5) | |
| Metastatic | 66 (64.1) | 14 (82.4) | 52 (60.5) | |
| Primary site, n (%) | 0.17 | |||
| Pancreatic head | 46 (44.7) | 5 (29.4) | 41 (47.7) | |
| Pancreatic body | 39 (37.9) | 6 (35.3) | 33 (38.4) | |
| Pancreatic tail | 18 (17.4) | 6 (35.3) | 12 (13.9) | |
| Comorbidities and VTE risk factors non-related to cancer, n (%) | 0.59 | |||
| Hypertension | 22 (21.4) | 5 (29.4) | 17 (19.8) | |
| Hyperlipidemia | 6 (5.8) | 0 (0.0) | 6 (7.0) | |
| Diabetes | 15 (14.6) | 2 (11.8) | 13 (15.1) | |
| Infection | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Total bed rest with bathroom privileges for >3 days, n (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | – |
| CAD, n (%) | 1 (1.0) | 0 (0.0) | 1 (1.1) | – |
| Brinkman index, mean | 280 | 345 | 268 | 0.47 |
| Smoking status, n (%) | 0.42 | |||
| Non-smoker | 59 (57.2) | 8 (47.1) | 51 (59.3) | |
| Smoker | 22 (21.4) | 3 (17.6) | 19 (22.1) | |
| Ex-smoker | 22 (21.4) | 6 (35.3) | 16 (18.6) | |
| CA19-9 level (U/mL), median (range) | 854.0 (1.0–356,700) | 1,516.0 (39.0–356,700.0) | 686.5 (1.0–6,780.0) | 0.22 |
Abbreviations: BMI, body mass index; CA19-9, carbohydrate antigen 19-9; CAD, coronary artery disease; PS, performance status.